Clinical–MRI correlations in a European trial of interferon beta-1b in secondary progressive MS

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Neurology

• Publication date

  2001-12-26

• Fields of study

  Medicine

• Identifiers
  DOI 10.1212/WNL.57.12.2191PMID 11756596
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Placebo-controlled multicentre randomised trial of interferon (cid:1) -1b in treatment of secondary progressive multiple sclerosis

  2005cited by this paper
• T(1) hypointense lesions in secondary progressive multiple sclerosis: effect of interferon beta-1b treatment.

  2001cited by this paper
• The effect of interferon beta-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis. European Study Group on Interferon beta-1b in secondary progressive multiple sclerosis.

  2000cited by this paper
• The effect of interferon beta-1 b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis

  2000cited by this paper
• Effect of interferon‐β1b on magnetic resonance imaging outcomes in secondary progressive multiple sclerosis: Results of a European multicenter, randomized, double‐blind, placebo‐controlled trial

  1999cited by this paper
• Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis. Gadolinium MRI Meta-analysis Group.

  1999cited by this paper
• Effect of interferon-beta1b on magnetic resonance imaging outcomes in secondary progressive multiple sclerosis: results of a European multicenter, randomized, double-blind, placebo-controlled trial. European Study Group on Interferon-beta1b in secondary progressive multiple sclerosis.

  1999cited by this paper
• Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS.

  1998cited by this paper
• Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

  1998cited by this paper
• Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group.

  1998cited by this paper
• Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group.

  1998cited by this paper
• MRI lesion volume measurement in multiple sclerosis and its correlation with disability: a comparison of fast fluid attenuated inversion recovery (fFLAIR) and spin echo sequences

  1998cited by this paper
• Guidelines for using quantitative measures of brain magnetic resonance imaging abnormalities in monitoring the treatment of multiple sclerosis

  1998cited by this paper
• Defining multiple sclerosis disease activity using MRI T2-weighted difference imaging.

  1998cited by this paper
• The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up.

  1998cited by this paper
• Precision and reliability for measurement of change in MRI lesion volume in multiple sclerosis: a comparison of two computer assisted techniques

  1998cited by this paper
• Magnetic resonance studies of intramuscular interferon β–1a for relapsing multiple sclerosis

  1998cited by this paper
• Correlations between monthly enhanced MRI Lesion rate and changes in T2 Lesion volume in multiple sclerosis

  1998cited by this paper
• Clinical and Magnetic Resonance Imaging Changes Correlate in a Clinical Trial Monitoring Cyclosporine Therapy for Multiple Sclerosis

  1997cited by this paper
• The Role of MRI in clinical trials of multiple sclerosis: Comparison of image processing techniques

  1997cited by this paper
• Serial gadolinium-enhanced MRI of the brain and spinal cord in early relapsing-remitting multiple sclerosis

  1996cited by this paper
• Quantification of MRI lesion load in multiple sclerosis: a comparison of three computer-assisted techniques.

  1996cited by this paper
• Clinical and Magnetic Resonance Imaging Predictors of Disability in Primary and Secondary Progressive Multiple Sclerosis

  1996cited by this paper
• Correlation between brain MRI lesion volume and disability in patients with multiple sclerosis

  1996cited by this paper
• Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis

  1996cited by this paper
• Interferon beta-1b in secondary progressive multiple sclerosis--outline of the clinical trial.

  1995cited by this paper
• Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group.

  1995cited by this paper
• Correlation between magnetic resonance imaging findings and lesion development in chronic, active multiple sclerosis

  1993cited by this paper
• Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosis

  1993cited by this paper
• The pathophysiology of acute optic neuritis. An association of gadolinium leakage with clinical and electrophysiological deficits.

  1991cited by this paper
• Duration and selectivity of blood-brain barrier breakdown in chronic relapsing experimental allergic encephalomyelitis studied by gadolinium-DTPA and protein markers.

  1990cited by this paper
• Rating neurologic impairment in multiple sclerosis

  1983cited by this paper

• The clinical-radiological paradox in multiple sclerosis: myth or truth?

  2022cites this paper
• Progressive Loss of Corneal and Retinal Nerve Fibers in Patients With Multiple Sclerosis: A 2-Year Follow-up Study

  2020cites this paper
• Trials of Licenced RRMS DMTs in Progressive MS

  2018cites this paper
• Predicting risk of secondary progression in multiple sclerosis: A nomogram

  2018cites this paper
• Comparison of magnetization transfer methods for assessing macromolecular bound water in the brain and cervical spinal cord

  2017cites this paper
• Mesenchymal stem cells and conditioned media in the treatment of multiple sclerosis patients: Clinical, ophthalmological and radiological assessments of safety and efficacy

  2017cites this paper
• Design, Synthesis, and Evaluation of Fluorinated Radioligands for Myelin Imaging.

  2016cites this paper
• A 10-year follow-up of the European multicenter trial of interferon β1 b in secondary-progressive multiple sclerosis

  2016cites this paper
• A 10-year follow-up of the European multicenter trial of interferon β-1b in secondary-progressive multiple sclerosis

  2016cites this paper
• Evaluating response to disease-modifying therapy in relapsing multiple sclerosis

  2015cites this paper
• Evaluation de traitement de la sclérose en plaques par analyses morphométriques de données d'imagerie par résonance magnétique

  2015cites this paper
• Histogram analysis of quantitative T1 and MT maps from ultrahigh field MRI in clinically isolated syndrome and relapsing–remitting multiple sclerosis

  2015cites this paper
• Betaferon® – MRI-Daten

  2013cites this paper
• Quality of life and depression in multiple sclerosis patients: longitudinal results of the BetaPlus study

  2012cites this paper
• Award Number: W81XWH-10-1-0843 TITLE: In Vivo PET Imaging of Myelin Damage and Repair in the Spinal Cord PRINCIPAL INVESTIGATOR: Robert Miller CONTRACTING ORGANIZATION: Case Western Reserve University

  2012cites this paper
• Myelin imaging compound (MIC) enhanced magnetic resonance imaging of myelination.

  2012cites this paper
• Interferon beta for secondary progressive multiple sclerosis.

  2012cites this paper
• Neuroimaging in Multiple Sclerosis

  2012cites this paper
• Neutralizing antibodies to interferon beta-1b multiple sclerosis: a clinico-radiographic paradox in the BEYOND trial

  2012cites this paper
• Predicting short-term disability progression in early MS : added value of MRI parameters

  2011cites this paper
• A myelin-specific contrast agent for magnetic resonance imaging of myelination.

  2011cites this paper
• Design, synthesis, and evaluation of coumarin-based molecular probes for imaging of myelination.

  2011cites this paper
• MRI Predictors for disability at 5 years after the diagnosis of MS

  2011cites this paper
• Refinement of the Clinical Scenario Evaluation Framework for Assessment of Competing Development Strategies with an Application to Multiple Sclerosis

  2010cites this paper
• A comparative assessment of cerebral white matter by magnetization transfer imaging in early- and adult-onset multiple sclerosis patients matched for disease duration

  2010cites this paper
• A novel PET marker for in vivo quantification of myelination.

  2010cites this paper
• Neutralizing Antibodies to Interferon-β and other Immunological Treatments for Multiple Sclerosis

  2009cites this paper
• In Vivo Quantification of Myelin Changes in the Vertebrate Nervous System

  2009cites this paper
• A Diffusion Tensor Imaging Investigation of White Matter in Pediatric Multiple Sclerosis Patients

  2009cites this paper
• Association between MRI parameters and the MS severity scale: a 12 year follow-up study

  2009cites this paper
• Magnetic Resonance Imaging Predictors for Disability in Multiple Sclerosis

  2008cites this paper
• MRI derived brain atrophy measures in multiple sclerosis

  2008cites this paper
• Clinical and conventional MRI predictors of disability and brain atrophy accumulation in RRMS

  2008cites this paper
• Magnetic resonance imaging as a surrogate outcome for multiple sclerosis relapses

  2008cites this paper
• A composite score to predict short-term disease activity in patients with relapsing-remitting MS

  2007cites this paper
• Normal-appearing grey and white matter T1 abnormality in early relapsing–remitting multiple sclerosis: a longitudinal study

  2007cites this paper
• Predicting short-term disability progression in early multiple sclerosis: added value of MRI parameters

  2007cites this paper
• Multiple Sclerosis and Demyelinating Diseases

  2007cites this paper
• Von der Neuroinflammation zur Neurodegeneration

  2006cites this paper
• Magnetization transfer MRI metrics predict the accumulation of disability 8 years later in patients with multiple sclerosis.

  2006cites this paper
• Magnetic resonance imaging as a surrogate outcome measure of disability in multiple sclerosis: Have we been overly harsh in our assessment?

  2006cites this paper
• Principal component and linear discriminant analysis of T1 histograms of white and grey matter in multiple sclerosis.

  2006cites this paper
• Secondary progressive multiple sclerosis: current knowledge and future challenges.

  2006cites this paper
• Sclerosis by a Human-Anti-Human IL-12 p 40 Nonhuman Primate Model of Multiple Suppression of Ongoing Disease in a

  2005cites this paper
• Increasing normal–appearing grey and white matter magnetisation transfer ratio abnormality in early relapsing–remitting multiple sclerosis

  2005cites this paper
• Suppression of Ongoing Disease in a Nonhuman Primate Model of Multiple Sclerosis by a Human-Anti-Human IL-12p40 Antibody1

  2005cites this paper
• 15 – MRI-Clinical Correlations in Multiple Sclerosis: Implications for Our Understanding of Neuronal Changes

  2005cites this paper
• Treatment with chimeric anti-human CD40 antibody suppresses MRI-detectable inflammation and enlargement of pre-existing brain lesions in common marmosets affected by MOG-induced EAE.

  2005cites this paper
• Short-term accrual of gray matter pathology in patients with progressive multiple sclerosis: an in vivo study using diffusion tensor MRI

  2005cites this paper
• Multiple Sclerosis: Other MR Techniques

  2005cites this paper
• Transkranielle Magnetstimulation bei multipler Sklerose

  2005cites this paper
• MRI evidence for multiple sclerosis as a diffuse disease of the central nervous system

  2005cites this paper
• Clinical–Magnetic Resonance Imaging Correlations in Multiple Sclerosis

  2005cites this paper
• Magnetisation transfer imaging in the study of early relapsing-remitting multiple sclerosis

  2005cites this paper
• Criteria to determine disability related to multiple sclerosis.

  2004cites this paper
• Evidence for grey matter MTR abnormality in minimally disabled patients with early relapsing-remitting multiple sclerosis

  2004cites this paper
• Modelling of multiple sclerosis: lessons learned in a non-human primate.

  2004cites this paper
• Exercise and Multiple Sclerosis

  2004cites this paper
• relapsing-remitting multiple sclerosis minimally disabled patients with early Evidence for grey matter MTR abnormality in

  2004cites this paper
• Short-term correlations between clinical and MR imaging findings in relapsing-remitting multiple sclerosis.

  2003cites this paper
• A functional magnetic resonance imaging study of patients with secondary progressive multiple sclerosis

  2003cites this paper
• MRI metrics as surrogate endpoints for EDSS progression in SPMS patients treated with IFN β-1b

  2003cites this paper
• Magnetic resonance-based techniques for the study and management of multiple sclerosis.

  2003cites this paper
• The use of quantitative magnetic-resonance-based techniques to monitor the evolution of multiple sclerosis.

  2003cites this paper
• Conventional and magnetization transfer MRI predictors of clinical multiple sclerosis evolution: a medium-term follow-up study.

  2003cites this paper
• Clinical trials and clinical practice in multiple sclerosis: Conventional and emerging magnetic resonance imaging technologies

  2002influential citation
• Magnetic Resonance Imaging of Multiple Sclerosis

  2002cites this paper
• Relapsing-Remitting Multiple Sclerosis and MR Imaging Findings in Short-Term Correlations between Clinical

  year unknowncites this paper
• A 10-year follow-up of the European multicenter trial of interferon beta-1 b in secondary-progressive multiple sclerosis

  year unknowncites this paper